Drug Profile
Ertugliflozin - Merck/Pfizer
Alternative Names: MK-8835; PF-04971729; PF-4971729; STEGLATROLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Merck & Co; Pfizer
- Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Discontinued Hypertension
Most Recent Events
- 30 Apr 2023 Merck and Seoul National University Bundang Hospital completes the phase III ERTU-GLS trial in Type-2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in South Korea (NCT03717194)
- 03 Jun 2022 Efficacy data from the phase III VERTIS CV trial in Type 2 diabetes mellitus presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)
- 15 Nov 2021 Efficacy data from the phase III VERTIS CV trial in Type 2 diabetes mellitus presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)